All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Weight loss projection

Future you

Enter your weight, goal, and compound to calculate 3, 6, and 12-month illustrations anchored to the STEP 1 or SURMOUNT-1 trial mean.

Calculation and sources updated .

This is a projection, not a prediction

The numbers this tool shows come from two large randomized trials. STEP 1 (Wilding et al., NEJM, 2021) followed 1,961 adults with obesity on 2.4mg weekly semaglutide for 68 weeks and found an average 14.9% body weight reduction against 2.4% on placebo. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) followed 2,539 adults on 5mg, 10mg, or 15mg weekly tirzepatide for 72 weeks and found averages of 15.0%, 19.5%, and 20.9%.

A group average does not describe each participant. The calculator uses the published mean as an endpoint and calculates a straight-line illustration between your starting weight and that endpoint.

Don't treat the output as your future. Use it to compare entered figures with published trial-group averages. Your body, your adherence, and your clinician's titration plan affect your actual response.

Projection Tool

Future You

See where you could be at 3, 6, and 12 months based on published clinical trial averages. These are straight-line illustrations, not guarantees.

How the projection is built

The calculation multiplies the trial's mean percentage loss by the fraction of the trial duration elapsed. Calendar months use 365.2425 days divided by 12. The model stops at the trial duration and does not continue losing weight indefinitely.

Semaglutide uses the STEP 1 mean of 14.9% at 68 weeks. Tirzepatide uses the SURMOUNT-1 treatment-regimen estimate of 20.9% at 72 weeks for the 15 mg group. The tool does not let you select a trial dose or simulate an individual titration schedule.

If the entered goal is reached along the illustration, later points stay at that goal. Pounds lost, percentage lost, and BMI all use that same displayed weight. Intermediate milestones are calculated values, not measurements reported by the trials.

A few caveats. The trial participants had BMI ≥ 30 or ≥ 27 with one comorbidity; the model doesn't check whether you match that. Trial participants got lifestyle counseling (500-kcal deficit target, 150 min/wk activity); the illustration references those treatment groups. Real-world response may differ from trial response.

Why your number will vary from the projection

Group averages. Trial results summarize participants assigned to a treatment group. They do not give this calculator a probability of success for an individual.

Inputs. Starting weight changes the illustrated pounds lost, while height changes BMI. Entered goal weight caps the illustration. Age, medical history, adherence, and treatment changes are not modeled.

Time course. Actual loss does not follow a constant weekly rate. The straight line is a transparent calculation between baseline and the trial endpoint, rather than a fitted clinical response curve.

Frequently asked

How are these milestones calculated?

The tool draws a straight line from your starting weight to the named trial's mean endpoint: 14.9% loss at 68 weeks for semaglutide 2.4 mg in STEP 1, or 20.9% at 72 weeks for tirzepatide 15 mg in SURMOUNT-1. It then calculates the 3, 6, and 12-month points. Those intermediate values are illustrations, not observed trial measurements or a prediction of your response.

What if I do not lose this much?

A trial mean does not specify what each participant lost. The tool has no personal-response model and cannot estimate how likely you are to reach an illustrated milestone. If you are weeks in and not moving, talk to your provider about dose adjustments rather than quitting.

What if I lose more?

The trial mean is not a maximum. The illustration does not assign a percentile to your result or model faster responders. Above-average loss is not automatically better. Losing more than 1% of body weight per week for sustained periods can cost lean mass, so most clinicians will slow titration if loss outpaces muscle retention.

Does this include diet and exercise?

STEP 1 and SURMOUNT-1 evaluated medication alongside lifestyle counseling, including a reduced-calorie diet and physical activity. This calculator uses those trial-group means; it does not separately measure or simulate your diet or activity.

Does the tool show trial percentile ranges?

No. A trial average alone does not establish the 25th or 75th percentile. The tool shows one calculated illustration for each milestone and does not fit a participant distribution.

Does this apply to compounded versions?

STEP 1 and SURMOUNT-1 studied specific branded trial formulations and treatment regimens. This calculator uses their results as reference endpoints and does not establish a compounded formulation's bioequivalence or expected clinical response. Bioequivalence has not been tested head-to-head in large trials, so the trial reference is not a guarantee.

Keep reading

Want a real treatment plan, not just a projection?

FormBlends licensed clinicians handle intake, labs, titration, and follow-up for compounded semaglutide and tirzepatide.

Start your consultation

Sources

Educational only. This tool does not provide medical advice, diagnose any condition, or recommend a course of treatment. Individual results vary. All medications described are compounded formulations containing the same active ingredients as their FDA-approved counterparts. Talk to your clinician before starting or changing any medication.